Nothing Special   »   [go: up one dir, main page]

HK1199418A1 - Formulations of active agents for sustained release - Google Patents

Formulations of active agents for sustained release

Info

Publication number
HK1199418A1
HK1199418A1 HK14113095.1A HK14113095A HK1199418A1 HK 1199418 A1 HK1199418 A1 HK 1199418A1 HK 14113095 A HK14113095 A HK 14113095A HK 1199418 A1 HK1199418 A1 HK 1199418A1
Authority
HK
Hong Kong
Prior art keywords
formulations
active agents
sustained release
sustained
agents
Prior art date
Application number
HK14113095.1A
Other languages
English (en)
Chinese (zh)
Inventor
Susan Arnold
Christopher Prior
Original Assignee
Phasebio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phasebio Pharmaceuticals Inc filed Critical Phasebio Pharmaceuticals Inc
Publication of HK1199418A1 publication Critical patent/HK1199418A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK14113095.1A 2011-08-24 2014-12-31 Formulations of active agents for sustained release HK1199418A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526940P 2011-08-24 2011-08-24
US201161551506P 2011-10-26 2011-10-26
PCT/US2012/052304 WO2013028989A1 (fr) 2011-08-24 2012-08-24 Formulations d'agents actifs pour une libération prolongée

Publications (1)

Publication Number Publication Date
HK1199418A1 true HK1199418A1 (en) 2015-07-03

Family

ID=47746903

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14113095.1A HK1199418A1 (en) 2011-08-24 2014-12-31 Formulations of active agents for sustained release

Country Status (7)

Country Link
US (2) US20130084277A1 (fr)
EP (2) EP4295858A1 (fr)
JP (1) JP6169079B2 (fr)
CN (1) CN104023784B (fr)
CA (1) CA2846209C (fr)
HK (1) HK1199418A1 (fr)
WO (1) WO2013028989A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
WO2009158704A2 (fr) 2008-06-27 2009-12-30 Duke University Agents thérapeutiques comprenant des peptides de type élastine
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CA2895156A1 (fr) 2012-12-21 2014-06-26 Sanofi Agonistes du glp1/gip double ou du glp1/gip/glucagon trigonal
WO2015086728A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
WO2015086730A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 non acylés
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
ES2818824T3 (es) 2014-05-08 2021-04-14 Phasebio Pharmaceuticals Inc Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3220936A4 (fr) 2014-11-21 2018-08-22 Phasebio Pharmaceuticals, Inc. Protéines de fusion elp pour libération contrôlée et prolongée
AU2016219513B2 (en) 2015-02-09 2021-09-30 Immunoforge Co., Ltd. Methods and compositions for treating muscle disease and disorders
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
KR102449167B1 (ko) 2016-05-06 2022-09-28 파세비오 파마수티컬스 인코포레이티드 제어된 지속 방출을 위한 elp 융합 단백질

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
EP2664340B1 (fr) * 2005-06-24 2020-02-12 Duke University Système d'administration directe de médicaments à base de biopolymères thermiquement sensibles
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1971355B1 (fr) * 2005-12-20 2020-03-11 Duke University Procedes et compositions pour l'administration d'agents actifs a proprietes pharmacologiques ameliorees
US7709227B2 (en) * 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
JP5395664B2 (ja) * 2006-09-06 2014-01-22 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 融合ペプチド治療用組成物
DK2155169T3 (en) * 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release
EP2190872B1 (fr) * 2007-09-05 2018-03-14 Novo Nordisk A/S Dérivés de glucagon-like peptide-1 et leur utilisation pharmaceutique
WO2009158704A2 (fr) * 2008-06-27 2009-12-30 Duke University Agents thérapeutiques comprenant des peptides de type élastine
WO2010080578A1 (fr) * 2008-12-18 2010-07-15 Phasebio Pharmaceuticals, Inc. Protéines biologiquement actives pouvant être activées par peptidase
IN2012DN02120A (fr) * 2009-08-14 2015-08-21 Phasebio Pharmaceuticals Inc
ES2669190T3 (es) * 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión

Also Published As

Publication number Publication date
EP4295858A1 (fr) 2023-12-27
CA2846209C (fr) 2022-04-05
CN104023784B (zh) 2018-05-25
EP2747832A1 (fr) 2014-07-02
CN104023784A (zh) 2014-09-03
EP2747832A4 (fr) 2015-01-07
US20130084277A1 (en) 2013-04-04
JP6169079B2 (ja) 2017-07-26
US20140171370A1 (en) 2014-06-19
JP2014524480A (ja) 2014-09-22
CA2846209A1 (fr) 2013-02-28
WO2013028989A1 (fr) 2013-02-28

Similar Documents

Publication Publication Date Title
HK1199418A1 (en) Formulations of active agents for sustained release
CY20222200002T2 (el) Βιοαποικοδομησιμα λιπιδια για την απελευθερωση δραστικων παραγοντων
HRP20180924T1 (hr) Sastavi za transdermalnu administraciju aktivnih sastojaka
HRP20161771T1 (hr) Formulacije bendamustina
IL228984A0 (en) Preparations and methods for stabilization of active agents
EP2785333A4 (fr) Compositions à libération prolongée à base de lipides amphipathiques
EP2790729A4 (fr) Formulations de particules à libération prolongée
CO6900117A2 (es) Formulaciones peptídicas de liberación controlada
ZA201208286B (en) Use of formulations having insecticidal activity
ZA201306016B (en) Bendamustine formulations
ZA201500137B (en) Dressing having sustained release of active agents
ZA201306643B (en) Formulation comprising phenylaminopyrimidine derivatives as active agent
ZA201308316B (en) Sustained release paracetamol formulations
ZA201305986B (en) Improved insecticide formulations
IL236466B (en) Pharmaceutical composition for the release of active components
IL228462B (en) The film-forming composition for sustained release depends on the ph of an active ingredient
EP2699094A4 (fr) Préparations de raltégravir de saveur masquée
RS58721B1 (sr) Sistem za produženo oslobađanje kozmetičkih sredstava
IL226237A0 (en) Pharmaceutical preparations for administration through the skin